FDA signals tighter enforcement on overstated claims for cancer drug

The FDA issued a warning to ImmunityBio over promotional claims connected to Anktiva. The agency cited repeated marketing assertions that the product—described in connection with bladder cancer—could treat all cancers, among other statements the FDA said were not supported by the required evidence.